May 2013 Array BioPharma (ARRY) entered into a Development and Commercialization Agreement with Oncothyreon (ONTY) to collaborate on development and commercialization of ONT380 for the treatment of cancer (previously known also as ARRY380). Upfront Payment Oncothyreon paid Array a onetime fee of $10MM This agreement was terminated effective December 11, 2014. December 2014, Array BioPharma […]